LaFleur & Godfrey LLC Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

LaFleur & Godfrey LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,055 shares of the medical research company’s stock after selling 330 shares during the period. Thermo Fisher Scientific comprises approximately 2.5% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 9th largest position. LaFleur & Godfrey LLC’s holdings in Thermo Fisher Scientific were worth $16,484,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC grew its position in Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC raised its holdings in Thermo Fisher Scientific by 61,754.7% during the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,105,677,000. Morgan Stanley boosted its position in shares of Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after purchasing an additional 1,764,312 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in shares of Thermo Fisher Scientific by 17,046.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after buying an additional 967,913 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 5,547 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the transaction, the chief executive officer now owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is owned by company insiders.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price target on the stock. HSBC assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 target price on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $0.22 during mid-day trading on Thursday, reaching $579.15. 338,541 shares of the company’s stock were exchanged, compared to its average volume of 1,606,165. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a 50-day moving average price of $564.32 and a two-hundred day moving average price of $519.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm has a market capitalization of $220.84 billion, a price-to-earnings ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the previous year, the business posted $5.40 EPS. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a $0.39 dividend. The ex-dividend date is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.